OpenNashPodcasts

Topic

Keytruda

11 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2026

Bancel said Moderna's randomized Phase 2 melanoma study, presented at ASCO in spring 2026, showed around 50% recurrence-free survival compared with Keytruda alone, five years after treatment.

“our phase two study, which was also randomized against Ketudra alone, so the same type of study, showed that around 50 % of people had recurrence-free survival versus people only getting Ketudra.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:05:42

2026

Bancel said Moderna is running a Phase 3 trial in lung cancer and Phase 2 trials in kidney and bladder cancer, combining the treatment with Keytruda.

“we are in phase three for lung. We're in phase two for kidney cancer, bladder cancer.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:31:36

Undated

Bancel said published Phase 3 data show only about 60% of patients are disease-free five years after Keytruda treatment.

“only 60 % of people are disease-free after five years. If you look at the phase three published data of Ketudra.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:07:32

Undated

Bancel said that patients treated with checkpoint inhibitors such as Keytruda commonly develop autoimmune conditions including type 1 diabetes, lupus and Crohn's disease.

“people that get checkpoints, whether it's Ketudra or any other type of checkpoints from other companies, they end up having type 1 diabetes, lupus, Crohn disease, these type of things.”

Stéphane Bancel · Moderna CEO Stéphane Bancel on the Next Era of mRNA, 0:07:57

Episodes